ABERRANT METHYLATION OF THE PROMOTER OF APC, CDH13 AND MGMT GENES IN COLORECTAL CANCER PATIENTS
https://doi.org/10.21294/1814-4861-2016-15-2-48-55
Abstract
Aberrant methylation of gene promoter regions is the main epigenetic change characterizing colorectal cancer. Methylation levels of 42 CpG-sites of promoter regions of the MGMT, APC and CDH13 genes in colorectal cancer were studied in comparison with methylation levels of the adjacent normal tissue in 25 patients. Pyrosequencing showed an increase in methylation levels of promoter regions of the MGMT, APC and CDH13 genes in tumor samples by 3 to 5 times. These tumor samples were screened for activating SNP-mutations in the KRAS (40 %), NRAS (0 %) and BRAF (0 %) oncogenes. SNP-mutations in the KRAS gene were accompanied by hypermethylation of one or more promoters of the studied genes. Association of this epigenetic index with tumor metastasis was proved. The data on an increase in methylation of the promoter regions of oncosupressor genes can be used as sensitive prognostic markers of progression and metastasis of colorectal cancer.
About the Authors
O. I. Kit
Rostov Cancer Research Institute of the Ministry of Health, 63, 14th line Street, 344037-Rostov-on-Don, Russia.
Russian Federation
MD, DSc, Professor, Director of the Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 1728-0329.
Russian Federation
MD, DSc, Professor, Director of the Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 1728-0329.
D. I. Vodolazhskiy
Rostov Cancer Research Institute of the Ministry of Health, 63, 14th line Street, 344037-Rostov-on-Don, Russia.
Russian Federation
PhD, Head of Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 6660-5361.
Russian Federation
PhD, Head of Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 6660-5361.
K. V. Dvadnenko
Rostov Cancer Research Institute of the Ministry of Health, 63, 14th line Street, 344037-Rostov-on-Don, Russia.
Russian Federation
MD, Senior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostovon-Don, Russia). SPIN-code: 4497-1769.
Russian Federation
MD, Senior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostovon-Don, Russia). SPIN-code: 4497-1769.
I. I. Efimova
Rostov Cancer Research Institute of the Ministry of Health, 63, 14th line Street, 344037-Rostov-on-Don, Russia.
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 1982-5034.
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 1982-5034.
E. N. Oleynikova
Rostov Cancer Research Institute of the Ministry of Health, 63, 14th line Street, 344037-Rostov-on-Don, Russia.
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 5840-4093.
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia). SPIN-code: 5840-4093.
D. D. Oleynikov
Rostov Cancer Research Institute of the Ministry of Health, 63, 14th line Street, 344037-Rostov-on-Don, Russia.
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia).
Russian Federation
Junior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostov-on-Don, Russia).
N. N. Timoshkina
Rostov Cancer Research Institute of the Ministry of Health, 63, 14th line Street, 344037-Rostov-on-Don, Russia.
Russian Federation
PhD, Senior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostovon-Don, Russia). SPIN-code: 9483-4330.
Russian Federation
PhD, Senior Researcher, Laboratory of Molecular Oncology, Rostov Research Institute of Oncology (Rostovon-Don, Russia). SPIN-code: 9483-4330.
References
1. Kornienko I.V., Vodolazhskij D.I., Vejko V.P., Shherbakov V.V., Ivanov P.L. Preparation of biological material for molecular-genetic identification surveys at mass admission of unidentified bodies. Rostov-on-Don: «Rostizdat», 2001. 256 p. [in Russian]
2. Odintsova I.N., Pisareva L.F., Hryapenkov A.V. Epidemiology of malignant tumors in the world // Sibirskij onkologicheskij zhurnal. 2015. № 5. P. 95–101. [in Russian]
3. Catalogue of somatic mutations in cancer – COSMIC (http://cancer.sanger.ac.uk/cosmic 11.11.2015).
4. Chen J., Rocken C., Lofton-Day C., Schulz H.U., Muller O., Kutzner N., Malfertheiner P., Ebert M.P. Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis // Carcinogenesis. 2005. Vol. 26 (1). P. 37–43.
5. Ding Z.Y., Jiang T., Piao Y., Han T., Han Y.L., Xie X.D. Meta-analysis of the association between APC promoter methylation and colorectal cancer // Onco Targets Ther. 2015. Vol. 5 (8). P. 211–222. doi: 10.2147/ OTT.S75827.
6. Esteller M. Molecular origins of cancer: epigenetics in cancer // N. Engl. J. Med. 2008. Vol. 358 (11). P. 1148–1096.
7. Grady W.M., Carethers J.M. Genomic and epigenetic instability in colorectal cancer pathogenesis // Gastroenterology. 2008. Vol. 135 (4). P. 1079–1099. doi: 10.1053/j.gastro.2008.07.076.
8. Hibi K., Nakao A. Lymph node metastasis is infrequent in patients with highly-methylated colorectal cancer // Anticancer Res. 2006. Vol. 26 (1A). P. 55–58.
9. Horvath S. DNA methylation age of human tissues and cell types // Genome Biol. 2013. Vol. 14 (10). R. 115.
10. Jass J.R. Colorectal cancer: a multipathway disease // Critical Reviews in Oncogenesis. 2006. Vol. 12 (3–4). P. 273–287.
11. Kit O.I., Vodolazhskiy D.I., Gevorkyan Y.A., Soldatkina N.V. KRAS gene mutations and gender differences in colorectal cancer // Int. J. Biomed. 2015. Vol. 5 (1). P. 11–15.
12. Kim M.S., Lee J., Sidransky D. DNA methylation markers in colorectal cancer // Cancer Metastasis Rev. 2010. Vol. 29 (1). P.181–206. doi: 10.1007/s10555-010-9207-6.
13. Kontic M., Stojsic J., Jovanovic D., Bunjevacki V., Ognjanovic S., Kuriger J., Puumala S., Nelson H.H. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathological characteristics of primary non small cell lung carcinoma // Clin. Lung Cancer. 2012. Vol. 13 (4). P. 297–303.c doi: 10.1016/j.cllc.2011.11.003.
14. Lof-Ohlin Z.M., Nilsson T.K. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes // Oncol. Rep. 2009. Vol. 21 (3). P. 721–729.
15. Nagasaka T., Sasamoto H., Notohara K., Cullings H.M., Takeda M., Kimura K., Kambara T., MacPhee D.G., Young J., Leggett B.A., Jass J. R., Tanaka N., Matsubara N. Colorectal сancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation // Clin. Oncol. 2004. Vol. 22 (22). P. 4584–4594.
16. Nakagawa H., Nuovo G.J., Zervos E.E., Martin E.W., Salovaara Jr.R., Aaltonen L.A., de la Chapelle A. Age-related hypermethylation of the 5’ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development // Cancer Res. 2001. Vol. 61 (19). P. 6991–6995.
17. Ogino S., Goel A. Molecular classification and correlates in colorectal cancer // J. Mol. Diag. 2008. Vol. 10 (1). P. 13–27. doi: 10.2353/jmoldx.2008.070082.
18. Patterson K., Molloy L., Qu W., Clark S. DNA Methylation: Bisulphite Modification and Analysis // J. Vis. Exp. 2011. Vol. 56. pii. 3170. doi: 10.3791/3170.
19. Phipps A.I., Limburg P.J., Baron J.A., Burnett-Hartman A.N., Weisenberger D.J., Laird P.W., Sinicrope F.A., Rosty C., Buchanan D.D., Potter J.D., Newcomb P.A. Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival // Gastroenterology. 2015. Vol. 148 (1). P. 77–87. doi: 10.1053/j.gastro.2014.09.038.
20. Taniguchi H., Yamazaki K., Yoshino T., Muro K., Yatabe Y., Watanabe T., Ebi H., Ochiai A., Baba E., Tsuchihara K. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients // Cancer Sci. 2015. Vol. 106 (3). P. 324–327. doi: 10.1111/cas.12595.
21. de Vogel S., Weijenberg M.P., Herman J.G., Wouters K.A., de Goeij A.F., van den Brandt P.A., de Bruine A.P., van Engeland M. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events // Ann Oncol. 2009. Vol. 20 (7). P. 1216–1222. doi: 10.1093/annonc/mdn782.
22. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., Nakamura Y., White R., Smits A.M., Bos J.L. Genetic alterations during colorectal tumor development // N. Engl. J. Med. 1988. Vol. 319 (9). P. 525–532.
Review
For citations:
Kit O.I., Vodolazhskiy D.I., Dvadnenko K.V., Efimova I.I., Oleynikova E.N., Oleynikov D.D., Timoshkina N.N. ABERRANT METHYLATION OF THE PROMOTER OF APC, CDH13 AND MGMT GENES IN COLORECTAL CANCER PATIENTS. Siberian journal of oncology. 2016;15(2):48-55. (In Russ.) https://doi.org/10.21294/1814-4861-2016-15-2-48-55
Views:
1024
Email this article 
